A. Loehr

发表

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

F. Feng, C. Higano, A. Bryce, 2020, Clinical Cancer Research.

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib

D. Petrylak, S. Watkins, A. Loehr, 2022, Frontiers in Oncology.

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

M. Burotto, A. Armstrong, L. Lacombe, 2022, Journal for ImmunoTherapy of Cancer.

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

James X. Sun, G. Morgan, B. Walker, 2018, Leukemia.

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

C. Higano, C. Sternberg, A. Bryce, 2021, Clinical Cancer Research.

Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.

A. Bryce, A. Patnaik, W. Abida, 2022, European urology.

Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients

C. Ryan, V. Assikis, Jim J. Xiao, 2021, Clinical research.

Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.

D. Morris, C. Ryan, V. Assikis, 2021 .

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration

W. Abida, B. Sautois, H. Schroeder, 2022, Current oncology.

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.

I. Bièche, F. André, O. Trédan, 2020, European journal of cancer.

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

C. Higano, C. Sternberg, A. Bryce, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

L. Dennis, B. Alexander, W. Abida, 2021, Clinical Cancer Research.

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.

M. Parmar, M. Sydes, R. Eeles, 2020, JCO precision oncology.

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

C. Redfern, A. Bryce, W. Abida, 2023, The New England journal of medicine.

Abstract 3650: Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

S. Orsulic, M. Raponi, T. Harding, 2017 .

Genomic loss of heterozygosity and survival in the REAL3 trial

A. Wotherspoon, D. Cunningham, T. Crosby, 2018, Oncotarget.

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

S. Srinivas, D. Josephs, N. Vogelzang, 2021, BMC Cancer.

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.

I. Bièche, F. André, C. Vicier, 2017 .

Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.

M. Parmar, M. Sydes, N. James, 2019, Journal of Clinical Oncology.

Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

S. Orsulic, M. Raponi, T. Harding, 2017 .

Primary endpoint analysis of the GEPARDUO study: Comparing dose-dense with sequential adriamycin/docetaxel combination as preoperative chemotherapy (PCHT) in operable breast cancer (T2-3, N0-2, M0)

J. Blohmer, M. Kaufmann, B. Gerber, 2003 .

RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).

I. Bièche, F. André, O. Trédan, 2019, Journal of Clinical Oncology.

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).

A. Bryce, A. Patnaik, W. Abida, 2020 .

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.

J. Burke, A. Bryce, A. Patnaik, 2023, European urology.

Becker Digital

M. Burotto, G. Gravis, J. Pérez-Gracia, 2022 .

Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies

W. Abida, Jingsong Zhang, D. Spaeth, 2019, Molecular and Cellular Biology / Genetics.